Screener
MoonLake Immunotherapeutics MLTX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(69,707) | $(40,559) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 845 | 378 |
| Share-based compensation expense | 13,355 | 2,290 |
| Net periodic pension benefit gain (loss) for the qualified pension plan | 11 | (4) |
| Other non-cash items | 422 | 124 |
| Changes in operating assets and liabilities: | ||
| Other receivables | (894) | (146) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's stock-based comp?
- MoonLake Immunotherapeutics (MLTX) reported stock-based comp of $13.36M in Q1 2026.
- How has MoonLake Immunotherapeutics's stock-based comp changed year-over-year?
- MoonLake Immunotherapeutics's stock-based comp increased by 483.2% year-over-year, from $2.29M to $13.36M.
- What is the long-term trend for MoonLake Immunotherapeutics's stock-based comp?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's stock-based comp has grown at a 10.1% compound annual growth rate (CAGR), from $9.65M to $12.9M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about MoonLake Immunotherapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude